ReviewmAbs

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns.

Orla Cunningham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.